Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Asthma Drug Petition Opposes OTC Approach, NSURE Paradigm

This article was originally published in The Tan Sheet

Executive Summary

The developing Rx-to-nonprescription switch paradigm should exclude asthma and anaphylaxis drugs, advocates argue in a citizen petition. They say making inhalers available OTC contradicts the current standard for care.


Related Content

Primatene Firm Expects Approval, Counts On Brand Equity, Target Market
FDA’s Broad Power Can Overcome NSURE Labeling Obstacles – Attorney
Extra-Label Communication Could Foster Novel Switch NDAs – Industry Attorney
Nephron Launches Asthma Inhaler Into Wide Open OTC Market
Teva Opposes Switching Asthma Drugs, Oral Contraceptives
Rescue Medicine Switch Concept Draws Criticism


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts